Abatacept for the Treatment of Giant Cell Arteritis

clinical trial

Wikidata entity: Q113888097



Quantities

P2899minimum age50
P1132number of participants78

P6099 clinical trial phase ... Q42824827 (phase III clinical trial) phase III clinical trial
P17 country ... Q16 (Canada) Canada
P17 country ... Q30 (United States) United States
P582 end time ... 2024-12-01 ???
P31 instance of ... Q30612 (clinical trial) clinical trial
P1050 medical condition ... Q707816 (giant cell arteritis) giant cell arteritis
P1050 medical condition ... Q1752891 (polymyalgia rheumatica) polymyalgia rheumatica
P4844 research intervention ... Q249619 (immunosuppressive drug) immunosuppressive drug
P4844 research intervention ... Q619908 (alkylating antineoplastic agent) alkylating antineoplastic agent
P4844 research intervention ... Q50349184 (immunologic factor) immunologic factor
P4844 research intervention ... Q2697833 (abatacept) abatacept
P4844 research intervention ... Q3271540 (mechanism of action) mechanism of action
P4844 research intervention ... Q39086981 (checkpoint inhibitor) checkpoint inhibitor
P4844 research intervention ... Q810254 (disease-modifying antirheumatic drug) disease-modifying antirheumatic drug
P6153 research site ... Q49117 (University of Pennsylvania) University of Pennsylvania
P6153 research site ... Q4117596 (Cleveland Clinic) Cleveland Clinic
P6153 research site ... Q1130172 (Mayo Clinic) Mayo Clinic
P8005 research subject recruitment status ... Q76649708 (recruiting) recruiting
P580 start time ... 2021-03-15 ???
P8363 study type ... Q78089383 (interventional study) interventional study
P1476 title Monolingualtext A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART) ???

External Ids
P3098ClinicalTrials.gov IDNCT04474847

Why not click here or view trends?

log id: 5408127